Indium-111–Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy
Authors:
- Cherry T. ThomasCTCherry T. Thomas
- Patrick T. BradshawPBPatrick T. Bradshaw
- Brad H. PollockBPBrad H. Pollock
- James E. MontieJMJames E. Montie
- Jeremy M.G. TaylorJTJeremy M.G. Taylor
- Howard D. ThamesHTHoward D. Thames
- Patrick W. McLaughlinPMPatrick W. McLaughlin
- David A. DeBioseDDDavid A. DeBiose
- David H. HusseyDHDavid H. Hussey
- Richard L. WahlRWRichard L. Wahl
- 1 May 2003
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (9) , 1715-1721
Abstract
Purpose: We evaluated the prognostic significance of indium-111 (111In)–capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In–capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95% confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95% CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95% CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.Keywords
This publication has 36 references indexed in Scilit:
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001
- COMPARISON OF HELICAL COMPUTERIZED TOMOGRAPHY, POSITRON EMISSION TOMOGRAPHY AND MONOCLONAL ANTIBODY SCANS FOR EVALUATION OF LYMPH NODE METASTASES IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN RELAPSE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCERJournal of Urology, 1999
- IN-111 CAPROMAB PENDETIDE MAB SCAN PREDICTS RESPONSE TO RADIOTHERAPY TO THE PROSTATE FOSSA IN MEN WITH TUMOR RECURRENCE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, 1999
- ( 111 ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 1998
- THERAPEUTIC IRRADIATION FOR PATIENTS WITH AN ELEVATED POST-PROSTATECTOMY PROSTATE SPECIFIC ANTIGEN LEVELJournal of Urology, 1997
- Consensus statement: Guidelines for PSA following radiation therapy1International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- The Use of Radiotherapy for Patients with Isolated Elevation of Serum Prostate Specific Antigen Following Radical ProstatectomyJournal of Urology, 1996
- Preliminary Imaging Results Using In-111 Labeled CYT-356 (Prostascintst) in the Detection of Recurrent Prostate CancerClinical Nuclear Medicine, 1996
- Radioimmunoscintigraphy of prostate cancerSeminars in Nuclear Medicine, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958